Teneligliptin-induced polyarthritis: A case report

Rationale: DPP4 inhibitors are very important armamentarium for the management of type 2 diabetes mellitus. Usually, dipeptidyl peptidase-4 (DDP-4) inhibitors are free from side effects. Patient Concern: We report a case of teneligliptin-induced polyarthritis. Diagnosis: The diagnosis is teneliglipt...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Prabhat Kumar Agrawal [verfasserIn] Nikhil Pursnani [verfasserIn] Ashish Gautam [verfasserIn] Boentika Singh [verfasserIn] Asvini Yadav [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2021

Schlagwörter:	acute joint pains ddp-4 inhibitor gliptin-induced polyarthritis teneligliptin

Übergeordnetes Werk:	In: Journal of Diabetology - Wolters Kluwer Medknow Publications, 2010, 12(2021), 4, Seite 528-529
Übergeordnetes Werk:	volume:12 ; year:2021 ; number:4 ; pages:528-529

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.4103/jod.jod_23_21

Katalog-ID:	DOAJ014061104

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ014061104
003	DE-627
005	20230502203939.0
007	cr uuu---uuuuu
008	230226s2021 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.4103/jod.jod_23_21 \|2 doi
035			\|a (DE-627)DOAJ014061104
035			\|a (DE-599)DOAJcb46bb8721dd46519ceff1da7252e31a
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC648-665
100	0		\|a Prabhat Kumar Agrawal \|e verfasserin \|4 aut
245	1	0	\|a Teneligliptin-induced polyarthritis: A case report
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Rationale: DPP4 inhibitors are very important armamentarium for the management of type 2 diabetes mellitus. Usually, dipeptidyl peptidase-4 (DDP-4) inhibitors are free from side effects. Patient Concern: We report a case of teneligliptin-induced polyarthritis. Diagnosis: The diagnosis is teneligliptin-induced seronegative, non-erosive, polyarthritis. Intervention: We stopped teneligliptin. Outcome: On stopping teneligliptin, arthralgia was relieved. Lesson: Acute joint pain (arthralgia)/arthritis can be an adverse effect of teneligliptin or DPP-4 inhibitors. Arthritis, as an adverse effect of teneligliptin, is first such case report to the best of our knowledge.
650		4	\|a acute joint pains
650		4	\|a ddp-4 inhibitor
650		4	\|a gliptin-induced polyarthritis
650		4	\|a teneligliptin
653		0	\|a Diseases of the endocrine glands. Clinical endocrinology
700	0		\|a Nikhil Pursnani \|e verfasserin \|4 aut
700	0		\|a Ashish Gautam \|e verfasserin \|4 aut
700	0		\|a Boentika Singh \|e verfasserin \|4 aut
700	0		\|a Asvini Yadav \|e verfasserin \|4 aut
773	0	8	\|i In \|t Journal of Diabetology \|d Wolters Kluwer Medknow Publications, 2010 \|g 12(2021), 4, Seite 528-529 \|w (DE-627)63560244X \|w (DE-600)2573347-3 \|x 20787685 \|7 nnns
773	1	8	\|g volume:12 \|g year:2021 \|g number:4 \|g pages:528-529
856	4	0	\|u https://doi.org/10.4103/jod.jod_23_21 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/cb46bb8721dd46519ceff1da7252e31a \|z kostenfrei
856	4	0	\|u http://www.journalofdiabetology.org/article.asp?issn=2078-7685;year=2021;volume=12;issue=4;spage=528;epage=529;aulast=Agrawal \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2078-7685 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 12 \|j 2021 \|e 4 \|h 528-529

Indexfelder

author_variant	p k a pka n p np a g ag b s bs a y ay
matchkey_str	article:20787685:2021----::eeilpiidcdoyrhii
hierarchy_sort_str	2021
callnumber-subject-code	RC
publishDate	2021
allfields	10.4103/jod.jod_23_21 doi (DE-627)DOAJ014061104 (DE-599)DOAJcb46bb8721dd46519ceff1da7252e31a DE-627 ger DE-627 rakwb eng RC648-665 Prabhat Kumar Agrawal verfasserin aut Teneligliptin-induced polyarthritis: A case report 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Rationale: DPP4 inhibitors are very important armamentarium for the management of type 2 diabetes mellitus. Usually, dipeptidyl peptidase-4 (DDP-4) inhibitors are free from side effects. Patient Concern: We report a case of teneligliptin-induced polyarthritis. Diagnosis: The diagnosis is teneligliptin-induced seronegative, non-erosive, polyarthritis. Intervention: We stopped teneligliptin. Outcome: On stopping teneligliptin, arthralgia was relieved. Lesson: Acute joint pain (arthralgia)/arthritis can be an adverse effect of teneligliptin or DPP-4 inhibitors. Arthritis, as an adverse effect of teneligliptin, is first such case report to the best of our knowledge. acute joint pains ddp-4 inhibitor gliptin-induced polyarthritis teneligliptin Diseases of the endocrine glands. Clinical endocrinology Nikhil Pursnani verfasserin aut Ashish Gautam verfasserin aut Boentika Singh verfasserin aut Asvini Yadav verfasserin aut In Journal of Diabetology Wolters Kluwer Medknow Publications, 2010 12(2021), 4, Seite 528-529 (DE-627)63560244X (DE-600)2573347-3 20787685 nnns volume:12 year:2021 number:4 pages:528-529 https://doi.org/10.4103/jod.jod_23_21 kostenfrei https://doaj.org/article/cb46bb8721dd46519ceff1da7252e31a kostenfrei http://www.journalofdiabetology.org/article.asp?issn=2078-7685;year=2021;volume=12;issue=4;spage=528;epage=529;aulast=Agrawal kostenfrei https://doaj.org/toc/2078-7685 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2021 4 528-529
spelling	10.4103/jod.jod_23_21 doi (DE-627)DOAJ014061104 (DE-599)DOAJcb46bb8721dd46519ceff1da7252e31a DE-627 ger DE-627 rakwb eng RC648-665 Prabhat Kumar Agrawal verfasserin aut Teneligliptin-induced polyarthritis: A case report 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Rationale: DPP4 inhibitors are very important armamentarium for the management of type 2 diabetes mellitus. Usually, dipeptidyl peptidase-4 (DDP-4) inhibitors are free from side effects. Patient Concern: We report a case of teneligliptin-induced polyarthritis. Diagnosis: The diagnosis is teneligliptin-induced seronegative, non-erosive, polyarthritis. Intervention: We stopped teneligliptin. Outcome: On stopping teneligliptin, arthralgia was relieved. Lesson: Acute joint pain (arthralgia)/arthritis can be an adverse effect of teneligliptin or DPP-4 inhibitors. Arthritis, as an adverse effect of teneligliptin, is first such case report to the best of our knowledge. acute joint pains ddp-4 inhibitor gliptin-induced polyarthritis teneligliptin Diseases of the endocrine glands. Clinical endocrinology Nikhil Pursnani verfasserin aut Ashish Gautam verfasserin aut Boentika Singh verfasserin aut Asvini Yadav verfasserin aut In Journal of Diabetology Wolters Kluwer Medknow Publications, 2010 12(2021), 4, Seite 528-529 (DE-627)63560244X (DE-600)2573347-3 20787685 nnns volume:12 year:2021 number:4 pages:528-529 https://doi.org/10.4103/jod.jod_23_21 kostenfrei https://doaj.org/article/cb46bb8721dd46519ceff1da7252e31a kostenfrei http://www.journalofdiabetology.org/article.asp?issn=2078-7685;year=2021;volume=12;issue=4;spage=528;epage=529;aulast=Agrawal kostenfrei https://doaj.org/toc/2078-7685 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2021 4 528-529
allfields_unstemmed	10.4103/jod.jod_23_21 doi (DE-627)DOAJ014061104 (DE-599)DOAJcb46bb8721dd46519ceff1da7252e31a DE-627 ger DE-627 rakwb eng RC648-665 Prabhat Kumar Agrawal verfasserin aut Teneligliptin-induced polyarthritis: A case report 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Rationale: DPP4 inhibitors are very important armamentarium for the management of type 2 diabetes mellitus. Usually, dipeptidyl peptidase-4 (DDP-4) inhibitors are free from side effects. Patient Concern: We report a case of teneligliptin-induced polyarthritis. Diagnosis: The diagnosis is teneligliptin-induced seronegative, non-erosive, polyarthritis. Intervention: We stopped teneligliptin. Outcome: On stopping teneligliptin, arthralgia was relieved. Lesson: Acute joint pain (arthralgia)/arthritis can be an adverse effect of teneligliptin or DPP-4 inhibitors. Arthritis, as an adverse effect of teneligliptin, is first such case report to the best of our knowledge. acute joint pains ddp-4 inhibitor gliptin-induced polyarthritis teneligliptin Diseases of the endocrine glands. Clinical endocrinology Nikhil Pursnani verfasserin aut Ashish Gautam verfasserin aut Boentika Singh verfasserin aut Asvini Yadav verfasserin aut In Journal of Diabetology Wolters Kluwer Medknow Publications, 2010 12(2021), 4, Seite 528-529 (DE-627)63560244X (DE-600)2573347-3 20787685 nnns volume:12 year:2021 number:4 pages:528-529 https://doi.org/10.4103/jod.jod_23_21 kostenfrei https://doaj.org/article/cb46bb8721dd46519ceff1da7252e31a kostenfrei http://www.journalofdiabetology.org/article.asp?issn=2078-7685;year=2021;volume=12;issue=4;spage=528;epage=529;aulast=Agrawal kostenfrei https://doaj.org/toc/2078-7685 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2021 4 528-529
allfieldsGer	10.4103/jod.jod_23_21 doi (DE-627)DOAJ014061104 (DE-599)DOAJcb46bb8721dd46519ceff1da7252e31a DE-627 ger DE-627 rakwb eng RC648-665 Prabhat Kumar Agrawal verfasserin aut Teneligliptin-induced polyarthritis: A case report 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Rationale: DPP4 inhibitors are very important armamentarium for the management of type 2 diabetes mellitus. Usually, dipeptidyl peptidase-4 (DDP-4) inhibitors are free from side effects. Patient Concern: We report a case of teneligliptin-induced polyarthritis. Diagnosis: The diagnosis is teneligliptin-induced seronegative, non-erosive, polyarthritis. Intervention: We stopped teneligliptin. Outcome: On stopping teneligliptin, arthralgia was relieved. Lesson: Acute joint pain (arthralgia)/arthritis can be an adverse effect of teneligliptin or DPP-4 inhibitors. Arthritis, as an adverse effect of teneligliptin, is first such case report to the best of our knowledge. acute joint pains ddp-4 inhibitor gliptin-induced polyarthritis teneligliptin Diseases of the endocrine glands. Clinical endocrinology Nikhil Pursnani verfasserin aut Ashish Gautam verfasserin aut Boentika Singh verfasserin aut Asvini Yadav verfasserin aut In Journal of Diabetology Wolters Kluwer Medknow Publications, 2010 12(2021), 4, Seite 528-529 (DE-627)63560244X (DE-600)2573347-3 20787685 nnns volume:12 year:2021 number:4 pages:528-529 https://doi.org/10.4103/jod.jod_23_21 kostenfrei https://doaj.org/article/cb46bb8721dd46519ceff1da7252e31a kostenfrei http://www.journalofdiabetology.org/article.asp?issn=2078-7685;year=2021;volume=12;issue=4;spage=528;epage=529;aulast=Agrawal kostenfrei https://doaj.org/toc/2078-7685 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2021 4 528-529
allfieldsSound	10.4103/jod.jod_23_21 doi (DE-627)DOAJ014061104 (DE-599)DOAJcb46bb8721dd46519ceff1da7252e31a DE-627 ger DE-627 rakwb eng RC648-665 Prabhat Kumar Agrawal verfasserin aut Teneligliptin-induced polyarthritis: A case report 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Rationale: DPP4 inhibitors are very important armamentarium for the management of type 2 diabetes mellitus. Usually, dipeptidyl peptidase-4 (DDP-4) inhibitors are free from side effects. Patient Concern: We report a case of teneligliptin-induced polyarthritis. Diagnosis: The diagnosis is teneligliptin-induced seronegative, non-erosive, polyarthritis. Intervention: We stopped teneligliptin. Outcome: On stopping teneligliptin, arthralgia was relieved. Lesson: Acute joint pain (arthralgia)/arthritis can be an adverse effect of teneligliptin or DPP-4 inhibitors. Arthritis, as an adverse effect of teneligliptin, is first such case report to the best of our knowledge. acute joint pains ddp-4 inhibitor gliptin-induced polyarthritis teneligliptin Diseases of the endocrine glands. Clinical endocrinology Nikhil Pursnani verfasserin aut Ashish Gautam verfasserin aut Boentika Singh verfasserin aut Asvini Yadav verfasserin aut In Journal of Diabetology Wolters Kluwer Medknow Publications, 2010 12(2021), 4, Seite 528-529 (DE-627)63560244X (DE-600)2573347-3 20787685 nnns volume:12 year:2021 number:4 pages:528-529 https://doi.org/10.4103/jod.jod_23_21 kostenfrei https://doaj.org/article/cb46bb8721dd46519ceff1da7252e31a kostenfrei http://www.journalofdiabetology.org/article.asp?issn=2078-7685;year=2021;volume=12;issue=4;spage=528;epage=529;aulast=Agrawal kostenfrei https://doaj.org/toc/2078-7685 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2021 4 528-529
language	English
source	In Journal of Diabetology 12(2021), 4, Seite 528-529 volume:12 year:2021 number:4 pages:528-529
sourceStr	In Journal of Diabetology 12(2021), 4, Seite 528-529 volume:12 year:2021 number:4 pages:528-529
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	acute joint pains ddp-4 inhibitor gliptin-induced polyarthritis teneligliptin Diseases of the endocrine glands. Clinical endocrinology
isfreeaccess_bool	true
container_title	Journal of Diabetology
authorswithroles_txt_mv	Prabhat Kumar Agrawal @@aut@@ Nikhil Pursnani @@aut@@ Ashish Gautam @@aut@@ Boentika Singh @@aut@@ Asvini Yadav @@aut@@
publishDateDaySort_date	2021-01-01T00:00:00Z
hierarchy_top_id	63560244X
id	DOAJ014061104
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ014061104</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502203939.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.4103/jod.jod_23_21</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ014061104</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJcb46bb8721dd46519ceff1da7252e31a</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC648-665</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Prabhat Kumar Agrawal</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Teneligliptin-induced polyarthritis: A case report</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Rationale: DPP4 inhibitors are very important armamentarium for the management of type 2 diabetes mellitus. Usually, dipeptidyl peptidase-4 (DDP-4) inhibitors are free from side effects. Patient Concern: We report a case of teneligliptin-induced polyarthritis. Diagnosis: The diagnosis is teneligliptin-induced seronegative, non-erosive, polyarthritis. Intervention: We stopped teneligliptin. Outcome: On stopping teneligliptin, arthralgia was relieved. Lesson: Acute joint pain (arthralgia)/arthritis can be an adverse effect of teneligliptin or DPP-4 inhibitors. Arthritis, as an adverse effect of teneligliptin, is first such case report to the best of our knowledge.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">acute joint pains</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ddp-4 inhibitor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">gliptin-induced polyarthritis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">teneligliptin</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the endocrine glands. Clinical endocrinology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nikhil Pursnani</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ashish Gautam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Boentika Singh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Asvini Yadav</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Diabetology</subfield><subfield code="d">Wolters Kluwer Medknow Publications, 2010</subfield><subfield code="g">12(2021), 4, Seite 528-529</subfield><subfield code="w">(DE-627)63560244X</subfield><subfield code="w">(DE-600)2573347-3</subfield><subfield code="x">20787685</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:528-529</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.4103/jod.jod_23_21</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/cb46bb8721dd46519ceff1da7252e31a</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.journalofdiabetology.org/article.asp?issn=2078-7685;year=2021;volume=12;issue=4;spage=528;epage=529;aulast=Agrawal</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2078-7685</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2021</subfield><subfield code="e">4</subfield><subfield code="h">528-529</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Prabhat Kumar Agrawal
spellingShingle	Prabhat Kumar Agrawal misc RC648-665 misc acute joint pains misc ddp-4 inhibitor misc gliptin-induced polyarthritis misc teneligliptin misc Diseases of the endocrine glands. Clinical endocrinology Teneligliptin-induced polyarthritis: A case report
authorStr	Prabhat Kumar Agrawal
ppnlink_with_tag_str_mv	@@773@@(DE-627)63560244X
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC648-665
illustrated	Not Illustrated
issn	20787685
topic_title	RC648-665 Teneligliptin-induced polyarthritis: A case report acute joint pains ddp-4 inhibitor gliptin-induced polyarthritis teneligliptin
topic	misc RC648-665 misc acute joint pains misc ddp-4 inhibitor misc gliptin-induced polyarthritis misc teneligliptin misc Diseases of the endocrine glands. Clinical endocrinology
topic_unstemmed	misc RC648-665 misc acute joint pains misc ddp-4 inhibitor misc gliptin-induced polyarthritis misc teneligliptin misc Diseases of the endocrine glands. Clinical endocrinology
topic_browse	misc RC648-665 misc acute joint pains misc ddp-4 inhibitor misc gliptin-induced polyarthritis misc teneligliptin misc Diseases of the endocrine glands. Clinical endocrinology
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Journal of Diabetology
hierarchy_parent_id	63560244X
hierarchy_top_title	Journal of Diabetology
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)63560244X (DE-600)2573347-3
title	Teneligliptin-induced polyarthritis: A case report
ctrlnum	(DE-627)DOAJ014061104 (DE-599)DOAJcb46bb8721dd46519ceff1da7252e31a
title_full	Teneligliptin-induced polyarthritis: A case report
author_sort	Prabhat Kumar Agrawal
journal	Journal of Diabetology
journalStr	Journal of Diabetology
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2021
contenttype_str_mv	txt
container_start_page	528
author_browse	Prabhat Kumar Agrawal Nikhil Pursnani Ashish Gautam Boentika Singh Asvini Yadav
container_volume	12
class	RC648-665
format_se	Elektronische Aufsätze
author-letter	Prabhat Kumar Agrawal
doi_str_mv	10.4103/jod.jod_23_21
author2-role	verfasserin
title_sort	teneligliptin-induced polyarthritis: a case report
callnumber	RC648-665
title_auth	Teneligliptin-induced polyarthritis: A case report
abstract	Rationale: DPP4 inhibitors are very important armamentarium for the management of type 2 diabetes mellitus. Usually, dipeptidyl peptidase-4 (DDP-4) inhibitors are free from side effects. Patient Concern: We report a case of teneligliptin-induced polyarthritis. Diagnosis: The diagnosis is teneligliptin-induced seronegative, non-erosive, polyarthritis. Intervention: We stopped teneligliptin. Outcome: On stopping teneligliptin, arthralgia was relieved. Lesson: Acute joint pain (arthralgia)/arthritis can be an adverse effect of teneligliptin or DPP-4 inhibitors. Arthritis, as an adverse effect of teneligliptin, is first such case report to the best of our knowledge.
abstractGer	Rationale: DPP4 inhibitors are very important armamentarium for the management of type 2 diabetes mellitus. Usually, dipeptidyl peptidase-4 (DDP-4) inhibitors are free from side effects. Patient Concern: We report a case of teneligliptin-induced polyarthritis. Diagnosis: The diagnosis is teneligliptin-induced seronegative, non-erosive, polyarthritis. Intervention: We stopped teneligliptin. Outcome: On stopping teneligliptin, arthralgia was relieved. Lesson: Acute joint pain (arthralgia)/arthritis can be an adverse effect of teneligliptin or DPP-4 inhibitors. Arthritis, as an adverse effect of teneligliptin, is first such case report to the best of our knowledge.
abstract_unstemmed	Rationale: DPP4 inhibitors are very important armamentarium for the management of type 2 diabetes mellitus. Usually, dipeptidyl peptidase-4 (DDP-4) inhibitors are free from side effects. Patient Concern: We report a case of teneligliptin-induced polyarthritis. Diagnosis: The diagnosis is teneligliptin-induced seronegative, non-erosive, polyarthritis. Intervention: We stopped teneligliptin. Outcome: On stopping teneligliptin, arthralgia was relieved. Lesson: Acute joint pain (arthralgia)/arthritis can be an adverse effect of teneligliptin or DPP-4 inhibitors. Arthritis, as an adverse effect of teneligliptin, is first such case report to the best of our knowledge.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	4
title_short	Teneligliptin-induced polyarthritis: A case report
url	https://doi.org/10.4103/jod.jod_23_21 https://doaj.org/article/cb46bb8721dd46519ceff1da7252e31a http://www.journalofdiabetology.org/article.asp?issn=2078-7685;year=2021;volume=12;issue=4;spage=528;epage=529;aulast=Agrawal https://doaj.org/toc/2078-7685
remote_bool	true
author2	Nikhil Pursnani Ashish Gautam Boentika Singh Asvini Yadav
author2Str	Nikhil Pursnani Ashish Gautam Boentika Singh Asvini Yadav
ppnlink	63560244X
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.4103/jod.jod_23_21
callnumber-a	RC648-665
up_date	2024-07-03T21:03:20.302Z
_version_	1803593292508561408
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ014061104</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502203939.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.4103/jod.jod_23_21</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ014061104</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJcb46bb8721dd46519ceff1da7252e31a</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC648-665</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Prabhat Kumar Agrawal</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Teneligliptin-induced polyarthritis: A case report</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Rationale: DPP4 inhibitors are very important armamentarium for the management of type 2 diabetes mellitus. Usually, dipeptidyl peptidase-4 (DDP-4) inhibitors are free from side effects. Patient Concern: We report a case of teneligliptin-induced polyarthritis. Diagnosis: The diagnosis is teneligliptin-induced seronegative, non-erosive, polyarthritis. Intervention: We stopped teneligliptin. Outcome: On stopping teneligliptin, arthralgia was relieved. Lesson: Acute joint pain (arthralgia)/arthritis can be an adverse effect of teneligliptin or DPP-4 inhibitors. Arthritis, as an adverse effect of teneligliptin, is first such case report to the best of our knowledge.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">acute joint pains</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ddp-4 inhibitor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">gliptin-induced polyarthritis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">teneligliptin</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the endocrine glands. Clinical endocrinology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nikhil Pursnani</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ashish Gautam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Boentika Singh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Asvini Yadav</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Diabetology</subfield><subfield code="d">Wolters Kluwer Medknow Publications, 2010</subfield><subfield code="g">12(2021), 4, Seite 528-529</subfield><subfield code="w">(DE-627)63560244X</subfield><subfield code="w">(DE-600)2573347-3</subfield><subfield code="x">20787685</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:528-529</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.4103/jod.jod_23_21</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/cb46bb8721dd46519ceff1da7252e31a</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.journalofdiabetology.org/article.asp?issn=2078-7685;year=2021;volume=12;issue=4;spage=528;epage=529;aulast=Agrawal</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2078-7685</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2021</subfield><subfield code="e">4</subfield><subfield code="h">528-529</subfield></datafield></record></collection>
score	7.399967

Nicht das Richtige dabei?

Schreiben Sie uns!

Teneligliptin-induced polyarthritis: A case report

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?